- Home
- ACIU vs HRTX Comparison
ACIU vs HRTX Comparison
Compare ACIU & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- HRTX
- Stock Information
- Founded
- ACIU 2003
- HRTX 1983
- Country
- ACIU Switzerland
- HRTX United States
- Employees
- ACIU N/A
- HRTX N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- HRTX Health Care
- Exchange
- ACIU Nasdaq
- HRTX Nasdaq
- Market Cap
- ACIU 213.3M
- HRTX 206.9M
- IPO Year
- ACIU 2016
- HRTX 1987
- Fundamental
- Price
- ACIU $2.48
- HRTX $1.24
- Analyst Decision
- ACIU Strong Buy
- HRTX Strong Buy
- Analyst Count
- ACIU 2
- HRTX 2
- Target Price
- ACIU $10.00
- HRTX $4.50
- AVG Volume (30 Days)
- ACIU 132.0K
- HRTX 1.5M
- Earning Date
- ACIU 11-04-2025
- HRTX 11-11-2025
- Dividend Yield
- ACIU N/A
- HRTX N/A
- EPS Growth
- ACIU N/A
- HRTX N/A
- EPS
- ACIU N/A
- HRTX N/A
- Revenue
- ACIU $36,362,036.00
- HRTX $149,694,000.00
- Revenue This Year
- ACIU N/A
- HRTX $10.62
- Revenue Next Year
- ACIU $1,022.98
- HRTX $12.99
- P/E Ratio
- ACIU N/A
- HRTX N/A
- Revenue Growth
- ACIU 86.71
- HRTX 9.78
- 52 Week Low
- ACIU $1.43
- HRTX $1.04
- 52 Week High
- ACIU $3.98
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- ACIU 64.11
- HRTX 30.45
- Support Level
- ACIU $2.12
- HRTX $1.25
- Resistance Level
- ACIU $2.35
- HRTX $1.35
- Average True Range (ATR)
- ACIU 0.13
- HRTX 0.06
- MACD
- ACIU 0.04
- HRTX 0.01
- Stochastic Oscillator
- ACIU 95.74
- HRTX 5.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.